Last updated: July 11, 2026
Litigation Summary and Analysis for Upsher-Smith Laboratories Inc. v. Zydus Pharmaceuticals (USA) Inc. (1:16-cv-00248): What Patent Claims Were Challenged, What Court Outcomes Followed, and What Launch Risk Remains
Upsher-Smith’s lawsuit against Zydus in case number 1:16-cv-00248 covers patent-listed rights tied to an FDA product regulated under the Hatch-Waxman framework. The litigation record determines (i) which patents were attacked through Paragraph IV theories, (ii) the court’s claim construction and invalidity/noninfringement findings, and (iii) whether a negotiated settlement created delayed generic entry. A complete, decision-grade summary requires the docket text and the operative filings that identify the specific Orange Book patents asserted, the patent claim numbers, the disposition of each asserted patent, and the entry of any final judgment or settlement order.
What is the case background for Upsher-Smith v. Zydus (1:16-cv-00248) and what FDA product is at issue?
Direct answer: The case is a Hatch-Waxman patent infringement matter filed by Upsher-Smith Laboratories Inc. against Zydus Pharmaceuticals (USA) Inc. under 28 U.S.C. § 2201/§ 2202 and 35 U.S.C. § 271(e)(2), docketed as 1:16-cv-00248. The specific drug, strength, dosage form, and asserted FDA application are determined by the Complaint and the related Orange Book list referenced in the pleadings.
What does “1:16-cv-00248” typically imply in Hatch-Waxman litigation?
In this fact pattern, the plaintiff alleges infringement based on a generic’s FDA Abbreviated New Drug Application (ANDA) containing a Paragraph IV certification to one or more Orange Book patents. The litigation record is usually anchored by:
- the Complaint identifying each asserted patent,
- the Answer/Counterclaims or early motions,
- a claim construction order for key terms,
- summary judgment or a trial decision,
- and any settlement agreement that may impose launch timing.
Which patents does Upsher-Smith assert in 1:16-cv-00248 and what claim elements were targeted?
Direct answer: The asserted patent set, their Orange Book listing numbers, and the specific claim elements are identified only in the case’s Complaint and claim chart. Without the docket filings that list the patents, the patent numbers, priority dates, and asserted claims cannot be stated accurately.
How to read the asserted-patent pattern in Upsher-Smith estates
In Upsher-Smith generic-blocking litigation, asserted rights frequently cluster into:
- composition or formulation patents (drug substance or specific blends),
- manufacturing and process patents,
- method-of-use patents (if the NDA label is tied to a protected indication),
- and device or coating-related patents if applicable.
The patent cluster in 1:16-cv-00248 must be confirmed by the pleadings.
What Paragraph IV challenges did Zydus raise in Upsher-Smith v. Zydus?
Direct answer: Paragraph IV challenges are defined by the ANDA certification and the generic’s asserted positions of noninfringement, invalidity, or both. The specific grounds (for example, anticipation, obviousness, lack of enablement, indefiniteness, or prosecution-history estoppel) appear in Zydus’s invalidity contentions and claim charts.
What typically appears in the invalidity theory in this case type?
Common Hatch-Waxman invalidity theories include:
- prior art anticipation under 35 U.S.C. § 102,
- obviousness under 35 U.S.C. § 103,
- written description and enablement under 35 U.S.C. § 112,
- and sometimes nonstatutory double patenting depending on the patent family structure.
These theories must be mapped to the actual filings in 1:16-cv-00248.
What court outcomes occurred: motions, claim construction, summary judgment, and final disposition?
Direct answer: Case outcomes in Hatch-Waxman matters are usually recorded through:
- a Markman (claim construction) order,
- dispositive motions for noninfringement/invalidity,
- judgment entered on the asserted patents,
- and any dismissal tied to settlement.
A litigation summary that is decision-grade requires the specific docket entries showing which patents survived and the final judgment date.
What does settlement look like in the docket for cases like 1:16-cv-00248?
If the parties settle, the docket often reflects:
- a joint stipulation of dismissal with prejudice as to some or all counts,
- or an order incorporating settlement terms,
- with a resulting entry date constraint for the generic.
Without the docket text, the presence and scope of any settlement cannot be stated.
What is the Orange Book status for the asserted patents in 1:16-cv-00248?
Direct answer: The Orange Book status is determined by the patents’ listing in the FDA Orange Book for the relevant NDA. For each asserted patent, a complete analysis requires:
- listing number and patent number,
- expiration date (patent term) and any pediatric exclusivity,
- whether the patent is listed as drug substance, drug product, or method,
- and whether other exclusivities (market exclusivity or exclusivity extension) impact entry.
This information is not derivable from the case number alone.
When do the Upsher-Smith patents expire and when could Zydus launch?
Direct answer: Launch timing turns on:
- the latest expiring asserted patent (including any terminal disclaimers),
- the effective date of any settlement or court-ordered stay,
- and any exclusivity blocks independent of patent status.
A timeline cannot be produced without the asserted patent expiration data and the docket’s final outcome.
How does Zydus’s ANDA posture affect litigation and entry risk?
Direct answer: In Hatch-Waxman litigation, the ANDA posture controls:
- which patents are in the case,
- whether the generic product is found noninfringing based on formulation/process differences,
- and whether later amendments or “carve-outs” remove infringement allegations.
A claim-level risk assessment requires the product identity and Zydus’s Paragraph IV certification details, which are set out in the ANDA-related filings.
What is the comparative patent strength of Upsher-Smith vs. Zydus in this matter?
Direct answer: Patent strength analysis in litigation depends on:
- the asserted claims’ survivability through claim construction,
- validity findings (anticipation/obviousness),
- and whether any noninfringement turns on essential structural elements.
Without the specific patents, asserted claim numbers, and outcomes, a strength score cannot be computed.
What generic entry risks exist after the litigation in 1:16-cv-00248?
Direct answer: Post-judgment or post-settlement entry risk is driven by:
- whether Upsher-Smith retained enforceable patents,
- whether a court held certain patents invalid,
- and whether other unasserted patents remain listed for the same drug.
A correct entry-risk statement requires the judgment record and the current Orange Book listing set tied to the asserted NDA.
What manufacturing or formulation/IP barriers could still block launch?
Direct answer: If the litigation results hinged on formulation, process, or method-of-use, launch can still be blocked by:
- the scope of any injunction entered (if any),
- and the presence of additional patents in the same family or continuation chain.
This cannot be mapped without the court’s claim-by-claim determinations.
Key Takeaways
- Case 1:16-cv-00248 is a Hatch-Waxman-style patent infringement action by Upsher-Smith against Zydus.
- Decision-grade litigation analysis requires the Complaint/Answer and the final disposition identifying the asserted Orange Book patents, claim numbers, and the court’s outcomes.
- Without the docket content that specifies the asserted patents and the judgment/settlement terms, a precise patent-by-patent summary and an accurate launch timeline cannot be produced.
FAQs
- What does “Paragraph IV” mean in Upsher-Smith v. Zydus 1:16-cv-00248?
- Which Orange Book patents were asserted in 1:16-cv-00248 and what are their expiration dates?
- Did the court in 1:16-cv-00248 construe claims, and which terms were most important?
- Was there a settlement in 1:16-cv-00248, and what launch timing did it impose?
- After judgment or dismissal, which other listed patents could still block Zydus entry?
References
- Court docket in Upsher-Smith Laboratories Inc. v. Zydus Pharmaceuticals (USA) Inc., No. 1:16-cv-00248.
